Hamostaseologie 2021; 41(S 01): S23
DOI: 10.1055/s-0041-1728123
Oral Communication
Megakaryocytes, Platelets & VWF

Platelets from patients with MYH9 related disorders are mechanically stiffer

L Sachs
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
,
J Baumann
2   Institute of Experimental Biomedicine – Chair I, University Hospital and Rudolf Virchow Center, Würzburg
,
J Wesche
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
,
P Nestler
3   ZIK HIKE – Center for Innovation Competence, Humoral Immune Reactions in Cardiovascular Diseases, University of Greifswald, Greifswald
,
C Zaninetti
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
,
L Lenkeit
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
,
A Greinacher
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
,
M Bender
2   Institute of Experimental Biomedicine – Chair I, University Hospital and Rudolf Virchow Center, Würzburg
,
O Otto
3   ZIK HIKE – Center for Innovation Competence, Humoral Immune Reactions in Cardiovascular Diseases, University of Greifswald, Greifswald
,
R Palankar
1   Institute for Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald
› Author Affiliations
 

Objective The MYH9 gene encodes for the heavy chain of non-muscle myosin IIA (NMMHC-IIA), which is involved in a variety of cellular processes that require biomechanical contractile force generation. Variants of MYH9 cause autosomal dominant MYH9-related disease (MYH9-RD) and are characterized by thrombocytopenia with giant platelets and mild to moderate bleeding tendency. Although the role of the cytoskeleton for platelet function is well known, the consequences of NMMHC-IIA mutations on platelet biomechanics are only poorly understood. To investigate this, high throughput functional mechanophenotyping was performed by real-time fluorescence and deformability cytometry (RT-FDC).

Material and Methods Using RT-FDC we analysed intrinsic biomechanics of single platelets from MYH9-RD patients with point mutations in the MYH9 gene that lead to following amino acid substitutions in NMMHC-IIA at positions p.D1424N and p.E1841K. For functional mechanophenotyping by RT-FDC, platelets were labelled with the platelet marker integrin β3 (CD61-PE) and with the platelet activation markers integrin αIIbβ3 (PAC1-FITC) and P-selectin (CD62P-AlexaFluor 647) while TRAP-6 was used as PAR1 agonist. Platelet F-actin content was determined by phalloidin-Atto 647 binding in flow cytometry.

Results Platelets from MYH9-RD patients showed two fold lower deformation (i. e. stiffer platelets) and were larger (p.D1424N: median deformation 0.0685, median size 9.63 µm2, n = 790 platelets and p.E1841K: 0.0686, 5.77 µm2, n = 955 platelets) than platelets from healthy individual (median deformation 0.1434, size 3.76 µm2, n = 1334 platelets). Upon TRAP-6 activation, platelets from healthy individuals became highly stiffer (Fold change: 2.87 fold, n = 962 single platelets) while platelets from MYH9-RD patients became only marginally stiffer (p.D1424N: 2.27 fold increase in stiffness compared to non-activated and E1841K: 1.9 fold increase in stiffness compared to non-activated). Quantification of basal F-actin content in non-stimulated MYH9-RD platelets was found to be two-fold higher than in the control platelets. With TRAP-6 activation, the F-actin level in control platelets increased more than in MYH9-RD platelets.

Conclusion We demonstrate that platelets from MYH9-RD, individuals with mutations in the MYH9 gene (p.D1424N and p.E1841K), are biomechanically stiffer with higher F-actin content than platelets from healthy individuals.



Publication History

Article published online:
18 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany